---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Vimseltinib Dihydrate - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/vimseltinib-dihydrate
version: v1
---

# Vimseltinib Dihydrate - NCI

# Vimseltinib Dihydrate

Placeholder slot

(vim-SEL-tih-nib dy-HY-drayt)

This page contains brief information about vimseltinib dihydrate
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Romvimza

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f73c7a62-9601-4df0-810f-100f515d79ea&audience=consumer)

## Use in Cancer

Vimseltinib dihydrate
is approved to treat adults with:

- **[tenosynovial giant cell tumor](/Common/PopUps/popDefinition.aspx?id=801209&version=Patient&language=English)** that is causing symptoms. It is used when surgery may make the symptoms worse or cause severe problems.

Vimseltinib dihydrate
is also being studied in the treatment of other conditions related to cancer.

## More About Vimseltinib Dihydrate

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/789223) - Detailed scientific definition and other names for this drug.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Vimseltinib Dihydrate](https://www.cancer.gov/research/participate/clinical-trials/intervention/C175876) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
